i-Base home
Search Menu
  • Home
  • Q and A
  • Questions by subject

Questions by subject

  • Access to treatment (324)
  • Adherence (651)
  • All topics (5,265)
  • CD4 and viral load (1,114)
  • Changing treatment (360)
  • Children (246)
  • Clinical trials (19)
  • Complications and coinfections (135)
  • COVID-19 (119)
  • Cure (75)
  • Disclosure (81)
  • Drug interactions (357)
  • HIV testing (457)
  • HIV transmission (942)
  • Injectable ART (10)
  • Life expectancy (93)
  • Living with HIV long-term (288)
  • Newly diagnosed (434)
  • Opportunistic infections (204)
  • Other tests (67)
  • PEP/PEPSE (247)
  • Pregnancy (499)
  • PrEP (141)
  • Recreational drugs (34)
  • HIV reinfection (superinfection) (61)
  • Research (21)
  • Resistance (159)
  • Sero different couples (209)
  • Sexual health (50)
  • Side effects (612)
  • Southern Africa (252)
  • Starting treatment (718)
  • Stopping treatment (66)
  • Supplements and herbs (184)
  • Support (228)
  • TB (22)
  • Transgender (6)
  • Travel (123)

Q and A

  • Ask a question
  • Recent questions
  • 18 top questions…
  • 12 top topics…
  • All topics
  • Factsheets
  • Q and A homepage

Archives

Home

  • i-Base homepage
  • Donate

This website sets no cookies from us or anyone else.

Information on this website is provided by treatment advocates and offered as a guide only. Decisions about your treatment should always be taken in consultation with your doctor.

HIV i-BASE
About us - Contact - Cookies and privacy - Copyright waiver - Terms of use - Home
Registered charity number: 1081905. Company number: 3962064.

Search i-Base

Site navigation

Quick links
HIV positive
Donate
Feedback
Advice and information
Q and A
Guides
HIV meds
Glossary
Research reports
HTB
HTB South
Pipeline report
Publications and resources
Publications
Other resources
Translations
Slide sets
Order and subscribe
Advocates' network
UK-CAB
Training manual
i-Base
About us
Contact
News and updates
Sitemap
Home
Find us on Facebook
i-Base on Facebook